论文部分内容阅读
目的观察ABO血型不合中药干预的临床效果。方法选择2010年1月—2013年12月就诊的115例O型血孕妇及其新生儿,随机分为对照组58例和观察组57例。对照组维生素C 0.2 g/次,3次/d;维生素B620 mg/次,3次/d;维生素E 50 mg/次,2次/d;均口服;吸氧1次/d,30 min/次;10 d为1个疗程。孕36周或37周开始口服鲁米那30 mg/次,2次/d,连用1疗程。观察组采用自拟的白芍甘草汤合茵陈大枣汤加减治疗。检测和记录两组新生儿5 min Apgar评分、新生儿脐带血黄疸、溶血病发生情况。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果对照组58例孕妇分娩58例新生儿,37例为生理性黄疸,21例为重度黄疸,8例发生溶血病。观察组57例孕妇分娩57例新生儿,48例为生理性黄疸,9例为重度黄疸,无溶血病发生。对照组脐带血胆红素、重度黄疸发生率、新生儿溶血病发生率分别为(33.9±7.5)μmol/L、36.2%(21/58)、13.8%(8/58),观察组分别为(28.5±5.2)μmol/L、15.8%(9/57)、0(0/57),两组比较差异均有统计学意义(均P<0.05)。对照组总有效率为53.4%,观察组为91.2%,两组比较差异有统计学意义(P<0.05)。结论围产期定期监测、孕期早期运用中药干预是治疗ABO血型不合、防止新生儿溶血性疾病的有效手段,值得临床推广应用。
Objective To observe the clinical effect of ABO incompatible drug intervention. Methods A total of 115 O-positive pregnant women and their newborns admitted to our hospital from January 2010 to December 2013 were randomly divided into control group (58 cases) and observation group (57 cases). Control group, vitamin C 0.2 g / time, 3 times / d; Vitamin B 620 mg / time, 3 times / d; Vitamin E 50 mg / time 2 times / Times; 10 d for a course of treatment. Pregnancy 36 weeks or 37 weeks of oral administration of luminal 30 mg / time, 2 times / d, once a course of treatment. Observation group with self-made white peony licorice soup and Yin Chen Dazao Decoction treatment. The 5-minute Apgar score and neonatal umbilical cord blood jaundice and hemolytic disease were detected and recorded. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results 58 cases of pregnant women in the control group delivered 58 newborns, 37 cases of physiological jaundice, 21 cases of severe jaundice, hemolytic disease in 8 cases. 57 cases of pregnant women in observation group delivered 57 newborns, 48 cases of physiological jaundice, 9 cases of severe jaundice, no hemolytic disease. The incidence of cord blood bilirubin, severe jaundice and neonatal hemolytic disease in the control group were (33.9 ± 7.5) μmol / L, 36.2% (21/58) and 13.8% (8/58), respectively (28.5 ± 5.2) μmol / L, 15.8% (9/57) and 0 (0/57), respectively. There was significant difference between the two groups (all P <0.05). The total effective rate was 53.4% in the control group and 91.2% in the observation group. The difference between the two groups was statistically significant (P <0.05). Conclusions Periodic monitoring of perinatal period and the intervention of traditional Chinese medicine in the early stage of pregnancy are effective methods to treat ABO blood group incompatibility and prevent hemolytic disease in newborns, which is worthy of clinical application.